One such LRRK2-specific inhibitor, MLi-2, has been found to be ~300x more selective for LRRK2 over other kinases and can readily cross the blood-brain barrier [13] demonstrating that it is possible to generate tool compounds that have clinical potential for therapeutic intervention in PD. The gene discussed is LRRK2; the disease is Parkinson disease.